1879-58-9

Usage

Uses

Used in Pharmaceutical Industry:
(3-Cyanophenoxy)acetic acid is used as a synthetic intermediate for the production of various pharmaceutically active substances. Its unique structure and reactivity allow for further chemical reactions that can lead to the development of therapeutic agents.
Used in Environmental Research:
(3-Cyanophenoxy)acetic acid is recognized as an environmental contaminant, and its presence in the environment is of interest to researchers studying the impact of chemical contaminants on ecosystems and human health. This role highlights the importance of understanding the behavior and effects of such compounds in the environment.

InChI:InChI=1/C9H7NO3/c10-5-7-2-1-3-8(4-7)13-6-9(11)12/h1-4H,6H2,(H,11,12)

Upstream product

• 873-62-1 m-cyanophenol 
• 79-11-8 chloroacetic acid 
• 308272-30-2 tert-butyl (3-cyanophenoxy)acetate 
• 55197-25-6 ethyl [(3-cyanophenyl)oxy]acetate 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 308288-85-9 4-[2-(3-cyano-phenoxy)-acetylamino]-benzoic acid methyl ester 
• 1616074-74-8 2-(3-cyanophenoxy)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)acetamide 
• 115464-36-3 <3-(aminomethyl)phenoxy>acetic acid 
• 308288-86-0 4-[2-(3-carbamimidoyl-phenoxy)-acetylamino]-benzoic acid 
• 308288-84-8 4-[2-(3-cyano-phenoxy)-acetylamino]-benzoic acid 

Relevant academic research and scientific papers

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity

Inhibiting the protein-protein interaction (PPI) between the transcription factor Nrf2 and its repressor protein Keap1 has emerged as a promising strategy to target oxidative stress in diseases, including central nervous system (CNS) disorders. Numerous non-covalent small-molecule Keap1-Nrf2 PPI inhibitors have been reported to date, but many feature suboptimal physicochemical properties for permeating the blood-brain barrier, while others contain problematic structural moieties. Here, we present the first side-by-side assessment of all reported Keap1-Nrf2 PPI inhibitor classes using fluorescence polarization, thermal shift assay, and surface plasmon resonance - and further evaluate the compounds in an NQO1 induction cell assay and in counter tests for nonspecific activities. Surprisingly, half of the compounds were inactive or deviated substantially from reported activities, while we confirm the cross-assay activities for others. Through this study, we have identified the most promising Keap1-Nrf2 inhibitors that can serve as pharmacological probes or starting points for developing CNS-active Keap1 inhibitors.

PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5- mediated disorders are also described.

Design and synthesis of glycolic and mandelic acid derivatives as factor Xa inhibitors

A series of glycolic and mandelic acid derivatives was synthesized and investigated for their factor Xa inhibitory activity. These analogues are highly potent and selective inhibitors against fXa. In a rabbit deep vein thrombosis model, compound 26 showed